N/A N=360 Alcohol Metabolism and Disease Risk in Asians
Healthy
Primary: Peak Number of Alcohol Drinks Consumed in a Day — 3.7; 4.2; 3.4; 3.0 drinks — p=.81
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants
Phase 2 N=60 Prevention of Alcohol Intolerance
Alcohol Sensitivity
Primary: Mean Area of Skin Erythema (Skin Redness) — 3.968; 1.739 centimeters^2
Phase 2 N=18 Use of F-652 in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: The Number of Subjects With Unexpected Serious Adverse Events. — 0; 0; 0 Participants
Phase 2 N=19 Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Metabolic Disease · Seizures
Primary: Change From Baseline on the Adaptive Behavior Assessment System (ABAS) Test at the End of the Study Drug and Placebo Treatment Periods — 5.2; 4.5 scores on a scale
Phase 3 N=91 Effects of SAMe in Patients With Alcoholic Liver Disease
Liver Disease, Alcoholic
Primary: Changes in Serum AST Levels — -13.5; -56 Units per liter (U/L)
N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
N/A N=94 Pharmacogenetics of Alcohol: Treatment Implications
Alcohol Related Disorders · Alcoholism · Alcohol Abuse
Primary: Breath Alcohol — 0.001; 0.075; 0.001; 0.071 gr/dL — p=0.28
Phase 2 N=87 Naltrexone for Individuals of East Asian Descent
Alcohol Use Disorder
Primary: Subjective Response - Craving for Alcohol — 1.7037; 1.9965; 2.1012; 1.8478 score on a scale — p=0.39
N/A N=33 Alcohol Biosensor Monitoring for Alcoholic Liver Disease
Alcohol Use, Unspecified
Primary: Alcohol Use — 7.4; 5.3; 4.4 drinks per episode
Phase 2 N=63 Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) · Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations · Emphysema or COPD
Primary: Within-individual % Change in Plasma Desmosine/Isodesmosine — 10.0619; 8.5627 % change
N/A N=40 The Effect of Whole Almonds on Biomarkers of Cardiovascular Disease in Chinese Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: The Major Nutrients of NCEP Step 2 Diet and Almond Diets — 17.5; 17.2; 38.4; 29.2 % of energy — p=<0.0001
N/A N=47 Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 2
Healthy
Primary: Change in Plasma 2-AAA Concentration From Baseline — -9.35; 7.02 ng/ml
Phase 1 N=17 Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3
Diabetes Mellitus, Type 2
Primary: Change in Level of 13C 2-AAA in Plasma — 1.742 uM*Hr
Phase 3 N=76 13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
Acute Liver Failure
Primary: Peak Percent Dose Recovery (PDR) Value — 10.2; 1.9 percentage per hour
Phase 2 N=15 Alpha Lipoic Acid in Geographic Atrophy
Age-Related Macular Degeneration
Primary: Phase I: Percentage of Participants With Adverse Events — 11; 10; 10 Participants — p=1.00
N/A N=180 Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
Alcoholism
Primary: Number of Drinks Felt Consumed at Baseline — 0; 0; 0; 0 drinks felt consumed
Phase 1 N=32 A Dose-escalating Clinical Trial With KH176
MELAS · LHON · Leigh Syndrome
Primary: SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF) — 386.2; 395.0; 385.8; 399.3 msec
Phase 2 N=47 Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
N/A N=60 Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
Fatty Liver Disease · Type 2 Diabetes · Impaired Glucose Regulation
Primary: Change of Liver Fat Content in % — -20.5; -15.5; -7.6; -7.3 absolute fat content change in %
Phase 2 N=109 Moderate Alcohol Intake Among Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: Glucose — -21.55; 1.92 mg/dL
Phase 2 N=82 Patients With Intermittent Claudication Injected With ALDH Bright Cells
Peripheral Artery Disease · Intermittent Claudication
Primary: Peak Walking Time (PWT) — 2.2; 1.2 minutes — p=0.238
Phase 2 N=23 Racial Differences in Vagal Control of Glucose Homeostasis
Obesity
Primary: Change in Oxidative Stress: Baseline to 2 Hours — -0.003; -0.006; 0.01; -0.006 pg /ml
Phase 4 N=13 High Dose or High Dose Frequency Study of Alglucosidase Alfa
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Glycogenesis 2 Acid Maltase Deficiency
Primary: Participants' Efficacy Response During the Treatment Period as Compared to Baseline for Participants With Respiratory Decline on Standard Treatment — 0; 0; 0; 1…
Phase 2 N=52 A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency
Pyruvate Kinase Deficiency
Primary: Percentage of Participants Experiencing at Least One Adverse Event (AEs) in the Core Period — 96.3; 100.0 percentage of participants
N/A N=30 Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling
Alcohol Consumption
Primary: Change in Bile Salt Metabolism (C4 )Levels to Determine Effect of FXR
N/A N=73 GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence
Alcoholism
Primary: Visual Analog Scales of Similarity to Alcohol - Baseline — 0; 0; 0; 0 units on a scale
N/A N=41 Fatty Acid Oxidation Defects and Insulin Sensitivity
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Primary: Glucose Disposal Rate (Rd)- the Rate of Glucose Infusion to Maintain Euglycemia During Steady State Insulin Infusion in mg/Min — 709; 429; 842; 497 mg/min — p=0.136
Phase 2 N=13 Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
Pompe Disease
Primary: Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. — 40,031; 29,638; 5,509,882; 1,907,161 mU/mL
Phase 1 N=34 Mavoglurant in Alcohol Drinking
Alcohol Drinking
Primary: Abnormal Labs and Adverse Events — 9; 8; 0; 0 Participants